Although the majority of ER+ breast cancer initially responds to endocrine therapy, approximately 15% to 20% of tumors inherently show resistance to the therapy and an additional 30% to 40% develop resistance over time [18]. This evidence concerns the gene ESR1 and breast carcinoma.